新股暗盤 | 雲康集團(2325.HK)暗盤段跌超5%
格隆匯5月17日丨據輝立證券,雲康集團(2325.HK)暗盤段現報7.45港元,較發行價7.89港元跌5.57%。公司主要為醫療機構提供全套診斷檢測服務,2019年至2021年收益分別為6.77億、12億、16.96億元人民幣,溢利分別為-3154.4萬、2.6億、3.81億元人民幣,每股有形資產淨值4.18港元,2021歷史市盈率10.65倍。此次上市發售1.38億股,其中香港發售1381.9萬股,國際發售1.24億股,每手500股,香港發售獲1.35倍認購,淨籌7.609億港元,當中約55%擬用於未來四年擴充及深化公司的醫聯體網絡。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.